918657-06-4

Upstream product

• 668470-83-5 (2S,3S)-(4-benzylmorpholin-2-yl)phenylmethanol 
• 847900-05-4 η⁶-(1-ethoxy-2-fluorobenzene)tricarbonylchromium 
• 94-71-3 2-Ethoxyphenol 
• 800407-92-5 (R)-phenyl[(2S)-4-(phenylmethyl)morpholin-2yl]methanol 
• 1005196-94-0 (2S,3S)-1-[benzyl-(2-hydroxyethyl)amino]-3-(2-ethoxyphenoxy)-3-phenylpropan-2-ol 
• 800407-90-3 (2R,3S)-4-benzyl-2-(hydroxyphenylmethyl)morpholin-3-one 
• 667876-79-1 (2S,3R)-4-benzyl-2-(bromophenylmethyl)morpholine 
• 98-88-4 benzoyl chloride 
• 1468-28-6 4-benzoylmorpholine 

Downstream Products

• 71620-89-8 (S,S)-reboxetine 

Relevant academic research and scientific papers

Dynamic kinetic resolution-based asymmetric transfer hydrogenation of 2-benzoylmorpholinones and its use in concise stereoselective synthesis of all four stereoisomers of the antidepressant reboxetine

Dynamic kinetic resolution-driven, asymmetric transfer hydrogenation reaction of 2-benzoylmorpholin-3-ones (4) proceeds efficiently to give the corresponding (2R,3S)- or (2S,3R)-2-(hydroxyphenylmethyl)morpholin-3-ones (6) with an excellent level of diastereo- and enantioselectivity and simultaneous control of two contiguous stereogenic centers in a single step. This process is employed to prepare all four stereoisomers of the antidepressant reboxetine.

Syntheses of (S,S)-reboxetine via a catalytic stereospecific rearrangement of β-amino alcohols

(Chemical Equation Presented) The formal total synthesis of (S,S)-reboxetine has been realized by two different approaches using a stereospecific rearrangement of β-amino alcohols catalyzed by (CF 3CO)2O.

NOREPINEPHRINE TRANSPORTER RADIOTRACERS AND METHODS OF SYNTHESES THEREOF

The present invention provides compounds and radiotracers thereof for locating, diagnosing, identifying, evaluating, detecting or quantitating NET by in vivo imaging. The invention also provides methods for locating, diagnosing, identifying, evaluating, detecting or quantitating NET, using radiotracers of high-affinity or labeled compounds of the invention, which exhibit low toxicity, can cross the blood-brain barrier and, preferably, distinguish among normal and abnormal brains. For example, a radiotracer of the invention can be administered to a patient in an amount suitable for in vivo imaging thereof. Preferably, radiotracers of the invention can also be used to locate, diagnosis, identify, evaluate, detect and quantitate NET in such diseases, disorders, conditions or maladies as, without limitation, depression, anxiety, ADHD and drug dependency.